Literature DB >> 33062180

Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities.

Arun K Ghosh1,1, Alessandro Grillo1,1, Jakka Raghavaiah1, Satish Kovela1, Megan E Johnson1, Daniel W Kneller2, Yuan-Fang Wang2, Shin-Ichiro Hattori3, Nobuyo Higashi-Kuwata3, Irene T Weber2, Hiroaki Mitsuya3,4,5.   

Abstract

The design, synthesis, biological evaluation, and X-ray structural studies are reported for a series of highly potent HIV-1 protease inhibitors. The inhibitors incorporated stereochemically defined amide-based bicyclic and tricyclic ether derivatives as the P2 ligands with (R)-hydroxyethylaminesulfonamide transition-state isosteres. A number of inhibitors showed excellent HIV-1 protease inhibitory and antiviral activity; however, ligand combination is critical for potency. Inhibitor 4h with a difluorophenylmethyl as the P1 ligand, crown-THF-derived acetamide as the P2 ligand, and a cyclopropylaminobenzothiazole P2'-ligand displayed very potent antiviral activity and maintained excellent antiviral activity against selected multidrug-resistant HIV-1 variants. A high resolution X-ray structure of inhibitor 4h-bound HIV-1 protease provided molecular insight into the binding properties of the new inhibitor.

Entities:  

Year:  2020        PMID: 33062180      PMCID: PMC7549267          DOI: 10.1021/acsmedchemlett.9b00670

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

Authors:  Yasuhiro Koh; Shintaro Matsumi; Debananda Das; Masayuki Amano; David A Davis; Jianfeng Li; Sofiya Leschenko; Abigail Baldridge; Tatsuo Shioda; Robert Yarchoan; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Biol Chem       Date:  2007-07-17       Impact factor: 5.157

Review 2.  Why do patients fail HIV therapy?

Authors:  L Waters; M Nelson
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

3.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

5.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 6.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

Authors:  Arun K Ghosh; Bruno D Chapsal; Irene T Weber; Hiroaki Mitsuya
Journal:  Acc Chem Res       Date:  2007-08-28       Impact factor: 22.384

7.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Azhar K Hussain; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

Review 8.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

9.  Resistance profile of darunavir: combined 24-week results from the POWER trials.

Authors:  Sandra de Meyer; Tony Vangeneugden; Ben van Baelen; Els de Paepe; Herwig van Marck; Gaston Picchio; Eric Lefebvre; Marie-Pierre de Béthune
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

10.  C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.

Authors:  Manabu Aoki; Hironori Hayashi; Ravikiran S Yedidi; Cuthbert D Martyr; Yuki Takamatsu; Hiromi Aoki-Ogata; Teruya Nakamura; Hirotomo Nakata; Debananda Das; Yuriko Yamagata; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.